- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
* Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALLXII/ECOG E2993. Blood, 2005 106: 3760-3767. * Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia .Blood,2006,107:1116-1123. * Treatment of Adult Acute Lymphoblastic Leukemia. American Society of Hematology, 2006. * Treatment of Adult Acute Lymphoblastic Leukemia. American Society of Hematology, 2006. * * 参见Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation ,2008,41:439–446. * 参见Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation ,2008,41:439–446. * Aversal, et al. Journal of Clinical Oncology, 2005, 23: 3447-3454. * Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion. American Society of Hematology, 2007. * Allogeneic transplantation for ALL in adults. Bone Marrow Transplantation ,2008,41:439–446. * The 5-year DFS after allogeneic SCT according to degree of chronic GVHD. No chronic GVHD 22 (10-36) %, limited chronic GVHD 53 (38-69) %, and extensive chronic GVHD 27(1-54) %. * Which Patients with Adult Acute Lymphoblastic Leukemia Should Undergo a Hematopoietic Stem Cell Transplantation? Case-Based Discussion. American Society of Hematology, 2007. * Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study。 Blood,2007,109:944-950. * * Ph+ALL单用化疗5年OS﹤10%。 在格列卫应用之前,MRC UKALLXII/ECOG E2993 结果显示, Ph+ALL 患者CR1期,有HLA相合供者进行Allo-HSCT,无HLA相合供者进行化疗,5年OS总体上在25%左右。多家文献报道异基因移植治疗CR1期Ph+ALL 患者,DFS可达30%-65%。 * The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449–3457. 29例Ph+ALL 患者诱导治疗CR者给予格列卫400-600mg/d,与巩固化疗同时率为79
文档评论(0)